Hospital-acquired Infections Market Size, Share and Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2024 – 2032

Hospital-acquired Infections Market Size, Share and Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2024 – 2032

Hospital-acquired Infections Market Size

Hospital-Acquired Infections Market size will expand at a notable pace over 2024-2032, credited to the rise in cosmetic surgeries and increasing social media influence.
 

The lack of basic hygiene services in healthcare facilities and the growing geriatric population are among the prominent reasons behind the increasing cases of hospital-acquired infections. As per the WHO’s report, between 2015 and 2050, the proportion of the global population aged 60 years or above will nearly double from 12% to 22%. The rate of hospitalization will therefore increase since elder people are susceptible to chronic diseases. Moreover, mounting investment to revitalize and strengthen public health infrastructures will bolster the need for HAI treatment.
 

Further, the aging population and increasing disposable income among consumers have contributed to the surge in aesthetic-focused practices. As individuals seek to maintain a youthful appearance and improve self-confidence, they are more willing to invest in cosmetic procedures and treatments offered by plastic surgery clinics. Additionally, the growing trend of medical tourism has expanded the reach of plastic surgery clinics, attracting patients from around the world who are seeking high-quality and affordable aesthetic procedures. This may lead to the prevalence of HAI.
 

Hospital-Acquired Infections Market Trends

There is a rising demand for innovative infection control technologies and products, such as UV disinfection systems, antimicrobial textiles, and advanced air purification systems, to supplement traditional infection control measures and reduce the transmission of pathogens in healthcare settings. This factor, along with regulatory initiatives and healthcare accreditation standards focusing on infection prevention & control are driving healthcare facilities to prioritize HAI reduction efforts and invest in evidence-based interventions. As a result, the HAI market is witnessing a shift towards comprehensive, multidisciplinary approaches to infection prevention, encompassing not only clinical interventions but also environmental, behavioral, and technological solutions.
 

Hospital-Acquired Infections Market Analysis

Urinary tract infection (UTI) segment is poised to grow substantially till 2032, given the escalating number of elective surgeries across private hospitals. Since catheters are required for bedbound patients after surgical procedures, the prevalence of UTI is projected to grow. Likewise, the high incidence of urinary incontinence among adult women will drive the implementation of hospital-acquired infection control strategies to limit urinary tract infections across healthcare settings.
 

The antifungal treatment segment is poised to showcase a decent growth trajectory through 2032, driven by the increasing incidence of fungal infections in healthcare settings, the growing population of immunocompromised patients, and the development of novel antifungal therapies. Fungal infections pose a significant risk to patients, particularly those with compromised immune systems or who have undergone invasive medical procedures. Antifungal treatments come handy for combating these fungal pathogens and improving patient outcomes.
 

Asia Pacific hospital-acquired infections market is set to gain traction over 2024-2032, driven by the rising prevalence of healthcare-associated infections, increasing healthcare spending, and expanding medical infrastructure. Countries like China, India, and Japan are witnessing rapid urbanization, demographic changes, and the emergence of new healthcare challenges, leading to a greater focus on infection prevention and control measures.
 

Hospital-Acquired Infections Market Share

Some of the key players in the hospital-acquired infections industry are

• Pfizer
• Abbott
• Bristol Myers Squibb
• GSK plc (formerly GlaxoSmithKline)
• Eli Lilly and Company
• Cipla
• Bayer
• Merck
• Daiichi Sankyo
• Johnson & Johnson
• F. Hoffmann-La Roche
• Cepheid (Danaher Corporation)
• AstraZeneca
   

These companies are focusing on innovative treatment launches, partnerships, and acquisitions to reinforce their footprint in the global industry.
 

Hospital-Acquired Infections Industry News

• In February 2024, Pfizer Inc. announced that VELSIPITY has received marketing authorization from the European Commission (EC) for the treatment of moderately to severely active ulcerative colitis (UC) in patients aged 16 years and older.

What Information does this report contain?